Form 8-K

8-K — Glucotrack, Inc.

Accession: 0001493152-26-040332

Filed: 2026-08-27

Period: 2026-08-27

CIK: 0001506983

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001506983

2026-08-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 27, 2026

GLUCOTRACK,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-41141

98-0668934

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

301

Rte. 17 North, Ste. 800, Rutherford, NJ

07070

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (201) 842-7715

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

GCTK

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §

230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure

August 27, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”),

which announced a 1-for-15 reverse stock split of the Company’s common stock, par value $0.001 per share, effective with the opening

of trading on August 31, 2026. The Press Release is furnished as Exhibit 99.1.

The

information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the

Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates

it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release dated August 27, 2026

104

Cover

Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

August 27, 2026

GLUCOTRACK,

INC.

By:

/s/

Erik Emerson

Name:

Erik

Emerson

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Glucotrack,

Inc. Announces Reverse Stock Split

1-for-15

reverse stock split to become effective as of the opening of trading on August 31, 2026

RUTHERFORD,

N.J., and LA JOLLA, C.A., August 27, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),

a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today

announced that it will effect a 1-for-15 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common

stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, August 31, 2026.

Glucotrack’s

Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK.” The new

CUSIP number for the Common Stock following the Reverse Stock Split will be 45824Q887.

The

material effects of the Reverse Stock Split will be:

● Every

15 shares of Glucotrack’s issued and outstanding Common Stock will be combined into

one (1) share of Common Stock.

● The

number of total outstanding shares of Common Stock will be proportionally reduced from 11,972,157

shares to approximately 798,144 shares.

● The

ownership percentage of each Glucotrack stockholder will remain unchanged, other than as

a result of fractional shares. No fractional shares of Common Stock will be issued in connection

with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to receive

fractional shares because they hold a number of shares not evenly divisible by the reverse

stock split ratio will automatically be entitled to receive an additional fraction of a share

of Common Stock to round up to the next whole share.

the annual meeting of stockholders held on August 18, 2026, the stockholders of the Company approved a proposal to authorize the Company’s

management to file one or more certificates of amendment to the Company’s certificate of incorporation to effect one or more reverse

stock splits at an aggregate ratio not to exceed 1-for-30, as determined by the Company’s management in its sole discretion.

Among

other considerations, the Reverse Stock Split is intended to bring Glucotrack into compliance with the $1.00 minimum bid price requirement

for maintaining the listing of its Common Stock on the Nasdaq Capital Market and to make the prevailing prices of its Common Stock more

attractive to a broader group of institutional investors. Following the Reverse Stock Split, the Company must maintain a closing bid

price of at least $1.00 for each trading day through November 9, 2026. In addition, if the Company becomes deficient with any other Nasdaq

listing requirement during the term of this exception, it will have seven (7) calendar days to present a plan to regain compliance to

the Nasdaq Hearings Panel (the “Panel”). The Panel will then determine whether to grant the Company an additional exception

period to cure the deficiency or to delist the Company. Accordingly, if the Company fails to maintain compliance with Nasdaq listing

requirements prior to November 9, 2026, its securities may be delisted at Nasdaq’s discretion.

The

combination of, and reduction in, the number of issued shares of Common Stock as a result of the Reverse Stock Split will occur automatically

at the opening of trading on August 31, 2026, without any additional action on the part of Glucotrack’s stockholders. Glucotrack’s

transfer agent, VStock Transfer, LLC, is acting as the exchange agent for the Reverse Stock Split and will send each stockholder a transaction

statement indicating the number of shares of Common Stock the stockholder holds after the Reverse Stock Split. Stockholders owning shares

via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject

to such broker’s particular processes. Such stockholders will not be required to take any action in connection with the Reverse

Stock Split.

Additional

information regarding the Reverse Stock Split can be found in the Company’s Definitive Proxy Statement on Schedule 14A, filed with

the U.S. Securities and Exchange Commission on July 17, 2026. A link to this document is available at https://www.sec.gov.

About

Glucotrack, Inc.

Glucotrack,

Inc. (NASDAQ: GCTK) operates Lōkahi Therapeutics™, a biopharmaceutical platform focused on advancing innovative therapeutic

opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through its ai² platform, Lōkahi

Therapeutics™ seeks to identify, evaluate, and advance differentiated healthcare and life sciences opportunities. For more information,

please visit www.lokahithera.com. In addition, through its subsidiary Glucotrack Technologies, Inc., the Company is focused on

the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous

blood glucose monitoring system. The Glucotrack CBGM is an investigational device and is limited by federal (or United States) law to

investigational use. For more information, please visit www.glucotrack.com. Information on the Company’s website does not

constitute a part of and is not incorporated by reference into this press release.

Forward-Looking

Statements

This

news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements

contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting

the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “intend”,

“plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based

on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate

only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking

statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking

statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results

anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects

on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results

and could cause such results to differ materially from any forward-looking statements that may be made in this news release. These factors

include, but are not limited to: the anticipated benefits of the Reverse Stock Split, including the effect the Reverse Stock Split will

have on the Company’s ability to regain and maintain compliance with the Nasdaq listing standards; the Company’s ability

to maintain a closing bid price of at least $1.00 for each trading day through November 9, 2026; the risk that the Company’s securities

may be delisted from Nasdaq if it fails to maintain compliance with applicable listing requirements; the ability to make the Company’s

Common Stock more attractive to institutional investors; the ability of Glucotrack to raise additional capital to finance its operations

(whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt

(and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients

in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability

to hire and retain qualified personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities

and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March

30, 2026.

Contacts:

Investor Relations:

ir@lokahithera.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 27, 2026

Entity File Number

001-41141

Entity Registrant Name

GLUCOTRACK,

INC.

Entity Central Index Key

0001506983

Entity Tax Identification Number

98-0668934

Entity Incorporation, State or Country Code

Entity Address, Address Line One

301

Rte. 17 North

Entity Address, Address Line Two

Ste. 800

Entity Address, City or Town

Rutherford

Entity Address, State or Province

Entity Address, Postal Zip Code

07070

City Area Code

(201)

Local Phone Number

842-7715

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

GCTK

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration